Sponsored by:

Nuclear Medicine: Page 185

Contrast agent & radiopharmaceutical market decline to continue
By AuntMinnie.com staff writers
A shrinkage in the U.S. contrast agent and radiopharmaceutical market that began in 2012 is projected to continue through 2017, according to a new report from market research firm Millennium Research Group.
December 23, 2012
Report: U.S. therapeutic radiopharma market set for growth
By Wayne Forrest
Fueled by new radiopharmaceuticals to treat various forms of cancer, U.S. sales of therapeutic radiopharmaceuticals over the next several years could reach $5.8 billion by 2020, according to a new market research report from Bio-Tech Systems.
December 19, 2012
Navidea submits Lymphoseek application to EMA
By AuntMinnie.com staff writers
Radiopharmaceutical developer Navidea Biopharmaceuticals has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for its investigational radiopharmaceutical Lymphoseek injection, an intraoperative lymphatic mapping agent.
December 18, 2012
GE, Merck ink deal on PET biomarker research
By AuntMinnie.com staff writers
GE Healthcare and pharmaceutical firm Merck have announced that they will collaborate on imaging biomarker research.
December 17, 2012
MITA lauds CMS PET tracer proposal
By AuntMinnie.com staff writers
The Medical Imaging and Technology Alliance (MITA) is lauding the proposal by the U.S. Centers for Medicare and Medicaid Services (CMS) to remove the national noncoverage decision for PET with radiopharmaceuticals for U.S. Food and Drug Administration-approved oncologic applications.
December 17, 2012
CMS proposal could ease payment path for oncology PET tracers
By Wayne Forrest
The U.S. Centers for Medicare and Medicaid Services (CMS) this week proposed a new policy that could make it easier for new oncology PET tracers to win reimbursement. PET advocates are disappointed, however, that the change won't apply to tracers used for neurology and cardiology applications.
December 13, 2012
Navidea draws on line of credit
By AuntMinnie.com staff writers
Radiopharmaceutical developer Navidea Biopharmaceuticals has completed an initial draw of $2 million from its line of credit with Platinum-Montaur Life Sciences.
December 11, 2012
Adding MRI and PET to biomarkers helps predict Alzheimer's
By Wayne Forrest
The combination of 1.5-tesla MRI, FDG-PET, and cerebrospinal fluid data when added to routine clinical tests significantly increases the ability to predict whether people with mild cognitive impairment will progress to Alzheimer's disease, according to a study published online December 11 in Radiology.
December 10, 2012
2012 12 11 10 07 12 730 Shaffer Mri Pet Alz Thumb
Eczacıbaşı-Monrol acquires Capintec
By AuntMinnie.com staff writers
Turkish radiopharmaceutical company Eczacıbaşı-Monrol Nuclear Products announced that it has purchased Capintec, a radiation measurement and nuclear medicine protection equipment company headquartered in Ramsey, NJ.
December 9, 2012
Absolute Imaging adds Mediso SPECT cameras to portfolio
By AuntMinnie.com staff writers
Absolute Imaging Solutions has signed a five-year, exclusive agreement to distribute SPECT cameras in the U.S. from Budapest, Hungary-based Mediso Medical Imaging Systems.
December 9, 2012
Positron wraps up 1st strontium-82 sale
By AuntMinnie.com staff writers
PET vendor Positron said that its wholly owned subsidiary Manhattan Isotope Technology has completed the first commercial sale and delivery of its active pharmaceutical ingredient (API)-grade strontium-82 to a North American pharmaceutical firm.
December 6, 2012
GE completes MBI install in Detroit
By AuntMinnie.com staff writers
GE Healthcare has installed its Discovery NM750b molecular breast imaging (MBI) system at the Barbara Ann Karmanos Cancer Institute in Detroit.
December 6, 2012
Previous Page
Page 185 of 440
Next Page